Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Cash & Equivalents (2022 - 2023)

Bluejay Diagnostics' Cash & Equivalents history spans 2 years, with the latest figure at $5.1 million for Q3 2023.

  • For Q3 2023, Cash & Equivalents fell 61.8% year-over-year to $5.1 million; the TTM value through Sep 2023 reached $5.1 million, down 61.8%, while the annual FY2022 figure was $10.1 million, N/A changed from the prior year.
  • Cash & Equivalents for Q3 2023 was $5.1 million at Bluejay Diagnostics, roughly flat from $5.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $17.1 million in Q1 2022 and bottomed at $5.1 million in Q3 2023.